True Health Medical Passes HKEX Listing Hearing; Core Percutaneous Surgical Robot Obtains NMPA Registration

NewTimeSpace · 2026/06/12 21:56 · By Yiming Yan

NewTimeSpace News: Guangdong True Health Medical Technology Development Co., Ltd. passed the main board listing hearing of the Hong Kong Stock Exchange on June 12, 2026, with China International Capital Corporation and DBS Group as joint sponsors. Founded in 2018, the company focuses on the R&D and commercialization of percutaneous puncture and ablation surgical robots. All four models of its core percutaneous puncture surgical robot have obtained Class III registration certificates from the National Medical Products Administration (NMPA), approved for use in lung and abdominal punctures. It is expected to become the first stock of puncture surgical robots in Hong Kong stocks.

NewTimeSpace News: According to the Hong Kong Stock Exchange disclosure, Guangdong True Health Medical Technology Development Co., Ltd. passed the main board listing hearing of the Hong Kong Stock Exchange on June 12, 2026, with China International Capital Corporation and DBS Group acting as joint sponsors.

Founded in 2018 and headquartered in Zhuhai, Guangdong, True Health Medical is a high-tech enterprise focusing on surgical robots in the soft tissue puncture diagnosis and treatment field, with AI and robot control as its core technologies. It isthe only company in China that has obtained approval for both percutaneous puncture and ablation surgical robots.

The company's core product, the percutaneous puncture surgical robot, has four models (TH-S1, TH-S, TH-S Pro, and TH-SA), all of which have obtained Class III registration certificates issued by the NMPA, approved for application in the diagnosis and treatment of lung and abdominal solid organ punctures. Among them,TH-S is recognized as "domestically innovative" by the NMPA, and TH-S1 is the first in China to fully integrate intelligent image analysis, puncture planning, optical navigation, robotic arm control, and respiratory tracking systems.

In addition, the company has two key products: the approved percutaneous microwave ablation surgical robots TH-X MW and TH-X HMW. Among them,TH-X MW is recognized as "internationally innovative" by the NMPA, and its indications for lung solid tumors have also been approved.

According to CIC data, True Health Medical has rankedfirst in China's percutaneous puncture and ablation surgical robot market for three consecutive years since 2022. As of the latest practicable date, its products have been clinically applied in 94 medical institutions across 23 key provinces in China, supporting more than 7,150 surgeries.

Tags：

True Health Technology IPO pass the listing hearing